Announced Mon, 10 Aug · 19:22 IST
Q1 FY27 Results: Revenue up 17% YoY, margins dip on Montreal costs
Mgmt Guided Margin ImprovementMgmt Guided Margin PressureOrder Pipeline DisclosedAnalyst Day Multiyear TargetsInvestor Communications View source PDFExplain this filing
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-8.1%1-day move
₹960.00
prior close
₹929.70
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.2+0.1+1.4+0.5-8.1-7.4-10.2-9.9-10.0-9.9————
Up moveDown movePending
AI summary
Jubilant Pharmova Q1 FY27 revenue grew 17% YoY to Rs 2,229 Cr. EBITDA fell 11% to Rs 268 Cr, margins dropped to 11.9% from 15.8% due to SPECT product unavailability and higher remediation costs at Montreal facility. PAT dropped 45% to Rs 56 Cr. Strong growth in Radiopharma (19%) and CDMO Sterile Injectables (34%). Management expects EBITDA margins to expand from H2 FY27.
Likely market impact
Mixed quarter: strong revenue growth but margins under pressure. Recovery expected from H2 FY27 as Montreal facility and SPECT products normalize.